Syndax Pharmaceuticals SNDX Increase Decrease In Collaboration Receivable
Increase Decrease In Collaboration Receivable at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept sndx:IncreaseDecreaseInCollaborationReceivable.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's increase decrease in collaboration receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's increase decrease in collaboration receivable?
- Syndax Pharmaceuticals (SNDX) reported increase decrease in collaboration receivable of $3.24M in Q1 2026.
- How has Syndax Pharmaceuticals's increase decrease in collaboration receivable changed year-over-year?
- Syndax Pharmaceuticals's increase decrease in collaboration receivable increased by 146.0% year-over-year, from -$7.04M to $3.24M.
- What does increase decrease in collaboration receivable mean?
- This tracks the change in amounts owed to the company by partners under collaboration or licensing agreements. It reflects the timing of revenue recognition versus cash collection for joint development activities.